Did hydroxychloroquine played crucial role as prophylactic drug against SARS-CoV-2 infection in resource-constrained and overloaded health care systems in countries like India: a prospective multicentre study in dedicated COVID hospitals
DOI:
https://doi.org/10.18203/2349-3933.ijam20205401Keywords:
Hydroxychloroquine, SARS-COV-2 infection, Health care workers, COVID-19, IgG seroprevalenceAbstract
Background: The Indian council medical research (ICMR) recommended to use hydroxychloroquine (HCQ) as a prophylactic agent against Severe acute respiratory syndrome coronavirus-2019 (SARS-COV-2) infection to cater need to protect high-risk individuals considering its pre-clinical data. This study explores role of HCQ in health care workers serving in coronavirus-2019 (COVID-19) pandemic.
Methods: The study was planned as multi center observational study, conducted from April, 2020 to August 2020 at COVID-19 hospitals in India. HCQ 400 mg twice a day on day-1 followed by 400 mg once weekly for next 7 weeks was administered to Health care workers (HCW). RTPCR test was conducted at 3 months post last dose of prophylaxis in symptomatic health care workers. IgG test was conducted in all participants at 3 months.
Results: We enrolled 1310 asymptotic frontline healthcare workers, of which 585 (45%) were male and 725 (55%) were female. Chi-Sqaure test statistical analysis in RTPCR Test showed p=0.515, p=0.634, p=0.00 in doctor and nurse, housekeeping and other staff respectively. Chi-Sqaure test statistical analysis in IgG antibody tests showed p=0.305, p=0.449 and p=o.345 in doctor and Nurse, Housekeeping and Other staff respectively.
Conclusions: HCQ did not provide statistically significant pre exposure prophylaxis to doctors, nurses and housekeeping staff. However for, “other staff members category” it showed highly statistically significant prophylaxis effect with respect to RTPCR positive test results in comparison with HCW who did not consume HCQ prophylaxis. And hence HCQ could certainly play a crucial role in resource-constrained and overloaded health care systems in countries like India.
References
Bhattacharya R, Chowdhury S, Mukherjee R, Nandi A, Kulshrestha M, Ghosh R et al. Pre exposure hydroxychloroquine prophylaxis for covid-19 in healthcare workers: a retrospective cohort. medRxiv. 2020.
Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology journal. 2005;2(1):1.
Recommendation for empiric use of hydroxychloroquine as prophylactic agent against SARS-CoV-2 infection in “health care workers”. Indian Council Medical Research Advisory. 2020.
Ianevski A, Andersen PI, Merits A, Bjørås M, Kainov D. Expanding the activity spectrum of antiviral agents. Drug Discovery Today. 2019;24(5):1224-8.
Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. The Lancet Infectious Diseases. 2020;20(10):1118-9.
Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(3):241-56.
Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents. 2020;20:105949.
BMJ India Correspondent Covid-19: Doctors criticise Indian research agency for recommending hydroxychloroquine prophylaxis. BMJ. 2020;369.
Kaur K, Kaushal S, Kaushal IG. Therapeutic status of hydroxychloroquine in COVID-19: A review. Journal of Anaesthesiology Clinical Pharmacology. 2020;36(1):S160.
Horby P, Landrain M. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. Nuffield Dept Population Health. 2020.
Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: A living systematic review. Ann Intern Med. 2020.
Wajnberg A, Mansour M, Leven E, Bouvier NM, Patel G, Firpo A et al. Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region. medRxiv. 2020.
M Day Covid-19: four fifths of cases are asymptomatic, China figures indicate. BMJ. 2020;m1375.
Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int J Biol Sci. 2020;16(10):1718.
